G1 Therapeutics announced recently that the U.S. Food and Drug Administration (FDA) has approved COSELA™ (trilaciclib) for injection. It is the first and only therapy designed to help protect bone marrow (myeloprotection) against extensive-stage small cell lung cancer (ES-SCLC) when administered prior to treatment with platinum/etoposide-containing regimen or topotecan-containing regimen. COSELA became commercially available in early March.
UI Pharmaceuticals is proud to have been able to support G1 Therapeutics Inc. by manufacturing clinical drug supplies of G1’s investigational drug therapy COSELA. We stand ready to collaborate with all our clients trying to accelerate their novel treatments through human clinical trials and into the marketplace.
About UI Pharmaceuticals:
UI Pharmaceuticals is the largest and most experienced university-affiliated FDA-registered pharmaceutical manufacturing facility in the United States that produces both sterile and non-sterile dosage forms, we have been developing formulations, manufacturing products, and conducting analytical testing for almost 45 years. UI Pharmaceuticals has a wide range of clients, partners, and collaborators that include both the U.S. and international companies, start-up organizations to mid-tier biotech companies, as well as government agencies.
UI Pharmaceuticals can support the development, manufacture, and all associated testing of preclinical, clinical, and commercial products.
For more information on G1 Therapeutics, Inc. and their drug development projects go to: